Unproven stem cell therapies
December 16, 2015 | Kirstin R.W. Matthews, Ana S. Iltis

Table of Contents
Author(s)
Kirstin R.W. Matthews
Fellow in Science and Technology PolicyAna S. Iltis
Nonresident Fellow for Biomedical Research PolicyThe U.S. Food and Drug Administration should work with stakeholders to develop new policy guidelines that prevent stem cell clinics from promoting unproven stem cell interventions to patients, the authors write in a Houston Chronicle op-ed.